Leveraging HDX-MS, XL-MS and AI for discovery of a transient druggable pocket in TNFa

Discovery and proteomic characterization of a novel KAT6A inhibitor -poster

Discovery and proteomic characterization of a novel KAT6A inhibitor -video

Identification of Protein Kinase Drug Targets Using Activity Estimation in Clinical Phosphoproteomics

A Novel Algorithm for the Harmonization of Pan-cancer Proteomics

Large scale clinical proteomics atlas enabled by novel harmonization algorithm

Drug Discovery Startup Protai Advances Complex Structure Prediction with AlphaFold, Proteomics, and NVIDIA NIM

Discovery of a novel KAT6A/B inhibitor with anti-tumor activity coupled with novel response biomarkers

A novel selective USP1 inhibitor coupled with a novel response biomarker

A large scale proteogenomic atlas for precision oncology

Integrative Proteomic Profiling in High-Grade Serous Ovarian Carcinoma: Unraveling Biomarkers and Therapeutic Targets

A novel USP1 inhibitor coupled with a novel proteomic response biomarker for precision oncology therapy-video

A novel USP1 inhibitor coupled with a novel proteomic response biomarker for precision oncology therapy-poster

A large scale proteogenomic atlas for precision oncology research-video

A large scale proteogenomic atlas for precision oncology research-poster

Phospho-proteomic dynamics reveal DNA damage and repair signatures of drug sensitivity-poster

Proteomics driven biomarker discovery for high-grade serous ovarian carcinoma from archived tissue specimens - video

Proteomics driven biomarker discovery for high-grade serous ovarian carcinoma from archived tissue specimens - poster

Proteomics platform identifies vulnerabilities for DNA damage repair drugs

Functional impact of protein-RNA variation in clinical cancer analyses

AACR 2023- What can we learn from phosphoproteomics compared to transcriptomics in DNA damage and other processes?

AACR 2023- Predictive biomarker discovery method to bridge the gap between preclinical disease model dose-response and clinical trials

AI drug discovery startup Protai raises $12M in seed funding

Protai adds $12 million to Seed round as it aims to build oncology drug discovery pipeline

Protai Expands Seed Round to $20M

Protai Adds $12 Million to Seed Round - to Build an Oncology Drug Discovery Pipeline

ASMS 2022- Artifical intelligence and proteomics: predicting genome-wide perturbation response

Proteogenomics of glioblastoma associates molecular patterns with survival

Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

Israel’s Protai comes out of stealth mode following $8M seed round

How Protai’s AI-powered platform is improving drug discovery

Protai Raises $8 Million Seed Round to Provide a Proteomics-based Platform for Faster and More Accurate Drug Discovery

Protai Raises $8M to Build Proteomics, AI-Based Drug Discovery Platform

Protai raises $8 million in Seed for its proteomics-based platform for drug discovery

Israeli AI drug discovery co Protai raises $8m

Using AI for drug discovery

With $8M seed round, Protai leverages the proteome to speed up drug discovery